Literature DB >> 25794320

[Optimising pain therapy for neurological inpatients].

W E Wurm1, A Lechner2, R Schmidt2, I S Szilagyi3, C Maier4, N Nestler5, B Pichler6, C Foussek6, H Bornemann-Cimenti3, A Sandner-Kiesling.   

Abstract

BACKGROUND: The Department of Neurology at the Medical University Graz has implemented a multiprofessional pain management concept and evaluated the outcome by means of a patient survey.
METHODS: Standard operating procedures for standardised pain measurement, documentation and therapy were developed. All engaged professional participants were trained before implementation.
RESULTS: 88.7 % of the surveyed 63 patients reported pain during the hospitalisation. During the night and in the morning, the occurrence of severe pain was most likely. The position or activity most likely triggering severe pain was mobilisation (19 %). Patients with degenerative diseases of the spine without radiculopathy reported the highest levels of pain.
CONCLUSIONS: Pain is an important problem for neurological inpatients. Nocturnal pain, pain induced by mobilisation, and pain therapy for patients with degenerative diseases of the spine without radiculopathy require particular attention. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2015        PMID: 25794320     DOI: 10.1055/s-0034-1399111

Source DB:  PubMed          Journal:  Fortschr Neurol Psychiatr        ISSN: 0720-4299            Impact factor:   0.752


  2 in total

Review 1.  [Pain - a neglected neurological issue].

Authors:  F Birklein; R Baron; C Gaul; C Maihöfner; O Rommel; A Straube; T Tölle; G Wasner
Journal:  Nervenarzt       Date:  2016-06       Impact factor: 1.214

2.  Implementation and maintenance of a pain management quality assurance program at intensive care units: 360 degree feedback of physicians, nurses and patients.

Authors:  Christian Smolle; Gerald Sendlhofer; Andreas Sandner-Kiesling; Michael K Herbert; Lydia Jantscher; Bernd Pichler; Lars-Peter Kamolz; Gernot Brunner
Journal:  PLoS One       Date:  2018-12-19       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.